BRPI0409653A - 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica - Google Patents

3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica

Info

Publication number
BRPI0409653A
BRPI0409653A BRPI0409653-3A BRPI0409653A BRPI0409653A BR PI0409653 A BRPI0409653 A BR PI0409653A BR PI0409653 A BRPI0409653 A BR PI0409653A BR PI0409653 A BRPI0409653 A BR PI0409653A
Authority
BR
Brazil
Prior art keywords
diphenylpropylamines
halogen
alkyl
tolterodine
optionally substituted
Prior art date
Application number
BRPI0409653-3A
Other languages
English (en)
Inventor
Raymond Charles Grabiak
Robert John Kaufman
John Gregory Slatter
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BRPI0409653A publication Critical patent/BRPI0409653A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/52—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Abstract

"3,3-DIFENILPROPILAMINAS (TOLTERODINA) SUBSTITUìDAS COM HALOGêNIO COM ATIVIDADE ANTIMUSCARìNICA". Novas 3,3-difenilpropilaminas da fórmula OR, e quaisquer dos seus estereoisómeros; em que R~ 1~ representa -H ou -CH~ 3~; R~ 2~ representa -CX~ 3~, -CR~ 2-1~X~ 2~, -CR~ 2-1~R~ 2-2~X OU -CR~ 2-1~R~ 2-2~H, em que X representa halogênio, e R~ 2-1~ e R~ 2-2~ representam, de um modo independente, -H ou -(alquila C~ 1~-C~ 4~), opcionalmente substituída com halogênio; R~ 3~ e R~ 4~ representam, de um modo independente, -H, -OCH~ 3~, -OH, -CONH~ 2~, -SO~ 2~NH~ 2~, -F, -Cl, -Br, -I, -CF~ 3~ ou -(alquila C~ 1~-C~ 4~), opcionalmente substituída com um ou dois -OH, -(alcoxila C~ 1~-C~ 4~), -COOH, ou -CO-O-(alquila C~ 1~-C~ 3~) ; e R~ 5~ e R~ 6~ representam, de um modo independente, alquila C~ 1~-C~ 6~, opcionalmente substituída com hidroxila, em que R~ 5~ e R~ 6~ contêm, em conjunto, pelo menos três átomos de carbono, e em que R~ 5~ e R~ 6~ podem formar um anel em conjunto com o nitrogênio da amina; com a condição de que R~ 2~ compreende pelo menos um halogênio; ou um seu sal de adição ácida fisiologicamente aceitável; as 3,3-difenilpropilaminas para utilização como medicamentos, utilização das 3,3-difenilpropilaminas para a preparação de medicamentos específicos e composições farmacêuticas compreendendo as 3,3-difenil-propilaminas. A presente invenção também inclui um método de tratamento que envolve a administração das 3,3-difenil-propilaminas.
BRPI0409653-3A 2003-04-25 2004-04-15 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica BRPI0409653A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46537203P 2003-04-25 2003-04-25
PCT/IB2004/001333 WO2004096751A1 (en) 2003-04-25 2004-04-15 Halogen substituted 3,3-diphenylpropylamines (tolterodine) having antimuscarinic activity

Publications (1)

Publication Number Publication Date
BRPI0409653A true BRPI0409653A (pt) 2006-04-25

Family

ID=33418235

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409653-3A BRPI0409653A (pt) 2003-04-25 2004-04-15 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica

Country Status (7)

Country Link
US (3) US20050004223A1 (pt)
EP (1) EP1620389A1 (pt)
JP (1) JP2006524677A (pt)
BR (1) BRPI0409653A (pt)
CA (1) CA2523226A1 (pt)
MX (1) MXPA05011509A (pt)
WO (1) WO2004096751A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
WO2003035599A1 (en) * 2001-10-26 2003-05-01 Pharmacia & Upjohn Company Quarternary ammonium compounds and their use as antimuscarinic agents
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
BRPI0409653A (pt) * 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica
KR101029643B1 (ko) 2004-07-24 2011-04-15 일동제약주식회사 엔-메틸-3,3-디페닐프로필아민의 제조방법
KR100647068B1 (ko) 2005-09-15 2006-11-23 하나제약 주식회사 라세믹ｎ,ｎ-디이소프로필-3-(2-히드록시-5-메틸페닐)-3-페닐프로판아민의 제조방법
CN100430370C (zh) * 2006-11-03 2008-11-05 华东理工大学 一种丙胺衍生物及其在制备托莫西汀中的应用
AU2008319397B2 (en) 2007-11-01 2013-01-31 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
WO2003035599A1 (en) * 2001-10-26 2003-05-01 Pharmacia & Upjohn Company Quarternary ammonium compounds and their use as antimuscarinic agents
BRPI0409653A (pt) * 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica

Also Published As

Publication number Publication date
CA2523226A1 (en) 2004-11-11
US20050004223A1 (en) 2005-01-06
JP2006524677A (ja) 2006-11-02
US7291648B2 (en) 2007-11-06
US7119121B2 (en) 2006-10-10
WO2004096751A1 (en) 2004-11-11
EP1620389A1 (en) 2006-02-01
US20060281812A1 (en) 2006-12-14
US20060004106A1 (en) 2006-01-05
MXPA05011509A (es) 2005-12-15

Similar Documents

Publication Publication Date Title
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
NZ515282A (en) Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions
BRPI0515218A (pt) composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
TW200720226A (en) Fluorinated derivatives of 4-(2-amino-1-hydroxiethyl)phenol as agonists of the β2 adrenergic receptor
BRPI0515860B8 (pt) derivados de tetralin e indano, seus usos, e composição farmacêutica
GEP20125379B (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BR0011324A (pt) Agonista de adrenoceptores beta 2
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
MA29213B1 (fr) Quinolones a substitution macrolones - amino
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR0215650A (pt) Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
JP2012505879A5 (pt)
TNSN05080A1 (en) NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published)
BRPI0409653A (pt) 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica
BRPI0514014A (pt) composto, uso do mesmo, composição farmacêutica, métodos para a terapia de dor, de ansiedade, e de mal de parkinson em um animal de sangue quente, e, processo para a preparação de um composto
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.